Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 85% · fresh
- Computed at
- 2026-10-01T00:22:26.065338+00:00
- Claimed
- 55
- Reported
- 55
- Verified
- 55
- Gap
- 0
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed and verified align
Evidence strength Critical
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-10-01
A commercially available U.S. treatment option within its approved breast-cancer indication.
- Why
- Randomized evidence demonstrates progression-free-survival benefit, with substantial toxicity and limited routine-care follow-up.
- Next
- Use oncology-led eligibility assessment, mutation testing and label-directed monitoring; follow final survival results and postmarketing evidence.
Constraints
Blockers
- Restricted indication and molecular eligibility
- Stomatitis, rash, hyperglycemia and hematologic toxicity
- Repeated intravenous infusions and monitoring burden
- Final overall-survival evidence remains pending
- Companion-diagnostic validation remains a postmarketing commitment
- Limited routine-care effectiveness and safety follow-up
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 9
- Tier 1
- 5
- Tier 2
- 4
- Tier 3
- 0
- Supports
- 5
- Contradicts
- 2
- Context
- 2
- Latest observed
- 2026-09-30
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-07-21 Reading moved from ready to ready.
- 2026-09-22 Reading moved from ready to ready.
- 2026-10-01 Reading moved from ready to ready.